No. The standard prophylactic regimen in the UK involves a single tablet taken once a week, beginning 1-2 weeks before travel and continuing for four weeks after leaving the malaria-endemic area.
Stop the medication and seek immediate ophthalmologic evaluation. Prompt detection of retinal toxicity can prevent permanent vision loss.
Chloroquine is classified as Category B in the UK, indicating it is generally considered safe, but it should be prescribed only when the benefit outweighs potential risk. Discuss travel plans with a obstetrician-gynecologist.
Both are 4-aminoquinolines, but hydroxychloroquine contains an additional hydroxyl group, resulting in a slightly different safety profile (lower risk of retinal toxicity) and different dosing conventions.
Chloroquine can cause hypoglycemia, especially in patients on insulin or sulfonylureas. Monitor blood glucose closely and adjust diabetic medication under medical supervision.
Most antidepressants do not interact directly, but certain SSRIs (e.g., citalopram) can prolong the QT interval. Discuss all current medications with your prescriber to assess cardiac risk.
Chloroquine is not a controlled substance in the UK and typically does not appear on standard occupational drug-testing panels. However, specific employer policies may vary.
Take the missed tablet as soon as you remember unless the next scheduled dose is due within 12 hours; do not double the dose. Continue the weekly schedule thereafter.
Yes, provided the container remains dry, airtight, and protected from heat and sunlight. Avoid leaving the medication at extreme temperatures during travel.
Yes. Chloroquine phosphate is marketed by several generic manufacturers and is available in 250 mg and 500 mg tablet forms under various brand names.
Chloroquine is a synthetic antiparasitic medication whose active ingredient is chloroquine phosphate. It belongs to the class of 4-aminoquinoline antimalarials and is supplied as oral pills, most commonly in 250 mg and 500 mg strengths. In the United Kingdom, chloroquine is a prescription-only medicine (Rx) regulated by the Medicines and Healthcare products Regulatory Agency (MHRA). It is primarily indicated for the prevention and treatment of malaria caused by susceptible Plasmodium species. Use of chloroquine for COVID-19 has been investigated but is not approved by the MHRA or other major regulatory bodies.
Chloroquine accumulates in the acidic food-vacuum compartments of the malaria parasite (the digestive vacuole). By raising the internal pH, it interferes with the parasite’s ability to detoxify heme, a toxic by-product of hemoglobin digestion. The buildup of toxic heme leads to parasite death.
In addition to its antimalarial action, chloroquine has immunomodulatory properties. It can inhibit cytokine release and reduce activation of certain immune cells, which sparked interest in its potential to modulate the inflammatory response seen in severe viral infections such as COVID-19. However, the clinical relevance of this mechanism for viral diseases remains unproven.
Key pharmacokinetic points:
Chloroquine is approved in the UK for:
These indications rely on chloroquine’s ability to eradicate blood-stage parasites and, in prophylaxis, to maintain therapeutic drug levels throughout exposure.
Note: Resistance to chloroquine is widespread in Plasmodium falciparum; therefore, it is not a first-line option for falciparum malaria in most regions.
During the early phase of the COVID-19 pandemic, chloroquine and its analogue hydroxychloroquine were investigated as potential treatments. Multiple randomized controlled trials and large observational studies have since shown no clinically meaningful benefit and have highlighted a higher risk of cardiac toxicity, especially QT-interval prolongation.
If a specific interaction is not listed, patients should disclose all medications, supplements, and herbal products to their prescriber.
This article provides educational information about chloroquine and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
